For men diagnosed with low-, intermediate-, and high-risk localized prostate cancer, Exact Sciences offers the Oncotype DX Genomic Prostate Score® (GPS) test, which measures the expression of certain genes in prostate cancer cells to help guide treatment decisions at the time of a patient’s diagnosis.1

The results are reported as a Genomic Prostate Score® result, which can help patients and their physicians make decisions about an appropriate management plan.2

With two tailored test reports, the GPS test provides useful information for when active surveillance may be an appropriate decision for low-risk patients, as well as risk estimates to help inform treatment decisions and treatment intensity for higher risk patients.3


 

1Klein et al. Eur Urol. 2014.

2Badani et al. Urol Pract. 2015.

3Data on file